TheEdgeResearch
Home / Stocks / AQSZF

Aequus Pharmaceuticals Inc. (AQSZF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$39,790
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.21
52-Wk Range
0.000199999995-0.008
CEO
Douglas Glen Janzen
Country
CA
Currency
USD

Aequus Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $39,790. On trailing twelve-month figures it carries a trailing P/E of 3.13, a net margin of 44.0%. Its beta of -0.21 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
3.13
Price / Sales
1.41
Price / Book
-0.10
EV / EBITDA
15.62
Gross margin
51.0%
Operating margin
-38.2%
Net margin
44.0%
Return on equity
—
Debt / equity
-0.87
Current ratio
0.03
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
12
IPO date
2015-06-16
Headquarters
Vancouver, BC, CA
About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company currently markets a range of products, including Vistitan, an ophthalmic treatment designed to alleviate elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Another key offering is Tacrolimus IR, an immunosuppressant vital for both preventing and treating acute rejection in organ transplant recipients. Aequus also provides its Evolve line of dry eye products, which target various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness, alongside a preservative-free ophthalmic option. In its development pipeline, Aequus is progressing several innovative candidates. These include Topiramate XR and Oxcarbazepine XR, extended-release oral tablets aimed at epilepsy treatment; AQS1303, a transdermal formulation of pyridoxine/doxylamine developed to combat nausea and vomiting during pregnancy; and AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. To support its market reach and innovation, Aequus has forged strategic alliances. These include an agreement with Sandoz Canada, Inc. for the promotion of Vistitan; a partnership with Supernus Pharmaceuticals, Inc. for the marketing of its extended-release anti-epileptic drugs; and a collaboration with Medicom Healthcare Ltd. centered on preservative-free ophthalmic treatments. Established in 2013, Aequus Pharmaceuticals Inc. maintains its corporate headquarters in Vancouver, Canada.

Comparable companies

Aequus Pharmaceuticals Inc. is most often compared with the following Healthcare names:

ACUSBIOAFDVLPHPMMIVIXFNEPTFNXENRMRKSHWZTOMDF
More research on AQSZF
AQSZF technical analysis AQSZF TheEdge Score Compare against peers
Open full interactive analysis & DCF →